Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for DT-818 (GeneTAC Modulator) in Myotonic Dystrophy Type-1 (DM1). The expected timing is based on the latest available company guidance and may change.
11/05/25:- DT-818 nominated for DM1; Ph1 MAD trial in Australia to start H1 2026. 03/09/26:- Ph1 MAD DM1 patient dosing expected H1 2026; study results anticipated in 2027. 04/28/26:- Ph1 MAD DM1 trial plans unchanged; patient dosing expected H1 2026, results in 2027. 06/30/26:- Ph1 MAD patient dosing initiated in DM1. Data expected in 2027. 08/03/26:- Ph1 MAD dosing reiterated; data expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.